Hot-melt sealing glass compositions and devices using the same
    8.
    发明授权
    Hot-melt sealing glass compositions and devices using the same 有权
    热熔密封玻璃组合物及使用其的装置

    公开(公告)号:US08786034B2

    公开(公告)日:2014-07-22

    申请号:US13608022

    申请日:2012-09-10

    IPC分类号: H01L29/84

    摘要: Hot-melt sealing glass compositions that include one or more glass frits dispersed in a polymeric binder system. The polymeric binder system is a solid at room temperature, but melts at a temperature of from about 35° C. to about 90° C., thereby forming a flowable liquid dispersion that can be applied to a substrate (e.g., a cap wafer and/or a device wafer of a MEMS device) by screen printing. Hot-melt sealing glass compositions according to the invention rapidly re-solidify and adhere to the substrate after being deposited by screen printing. Thus, they do not tend to spread out as much as conventional solvent-based glass frit bonding pastes after screen printing. And, because hot-melt sealing glass compositions according to the invention are not solvent-based systems, they do not need to be force dried after deposition.

    摘要翻译: 包括分散在聚合物粘合剂体系中的一种或多种玻璃料的热熔密封玻璃组合物。 聚合物粘合剂体系在室温下为固体,但在约35℃至约90℃的温度下熔融,由此形成可流动的液体分散体,其可施加到基底(例如盖片和 /或MEMS器件的器件晶片)。 根据本发明的热熔密封玻璃组合物在通过丝网印刷沉积之后快速再固化并附着到基底上。 因此,它们在丝网印刷后不会像常规的溶剂型玻璃料粘合膏一样扩散。 而且,由于根据本发明的热熔密封玻璃组合物不是溶剂型体系,它们在沉积后不需要强力干燥。

    METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS
    10.
    发明申请
    METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS 失效
    治疗肌肉条件的方法和组合

    公开(公告)号:US20120219521A1

    公开(公告)日:2012-08-30

    申请号:US13468956

    申请日:2012-05-10

    IPC分类号: A61K31/765 A61M25/00

    摘要: Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

    摘要翻译: 用于治疗心肌梗塞的方法,装置,试剂盒和组合物。 在一个实施例中,该方法包括防止脑室梗死区的重塑。 在其它实施方案中,该方法包括引入结构上增强剂。 在其它实施方案中,将药剂引入心室以增加心室的依从性。 在替代实施例中,预防重塑包括防止心室梗塞区变薄。 在另一个实施方案中,预防梗塞区的重塑和变薄包括胶原蛋白的交联和预防胶原蛋白滑脱。 在其它实施方案中,结构上增强剂可以伴随其它治疗剂。 这些药剂可以包括但不限于前成纤维细胞和血管生成剂。